Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 13, 2013 Category: Databases & Libraries Authors: Mayo Clinic Source Type: news

Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - June 13, 2013 Category: Hospital Management Authors: Mayo Clinic Source Type: news

Genetic Markers Could Focus Breast Cancer ChemopreventionGenetic Markers Could Focus Breast Cancer Chemoprevention
Newly discovered genetic markers could be used to select which women would benefit most from chemoprevention with tamoxifen and raloxifene. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Newly Identified Markers May Predict Who Will Respond To Breast Cancer Prevention Therapy
Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. Women who have the favorable variations of these two SNPs are more likely to respond to prevention therapy, according to this study... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Genetic variations may help identify best candidates for preventive breast cancer drugs
(Mayo Clinic) Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2013 Category: Cancer & Oncology Source Type: news

Newly identified markers may predict who will respond to breast cancer prevention therapy
(American Association for Cancer Research) Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2013 Category: Cancer & Oncology Source Type: news

Tamoxifen boost for breast cancer sufferers
Study finds that death rates fall significantly for patients who take the drug for 10 years rather than the standard fiveBreast cancer is less likely to recur if women previously treated for the disease take the drug tamoxifen for 10 years, instead of the recommended five, according to a British study. The study was a component of a larger international trial for which similar results were announced last year.Researchers estimated that, compared with taking no tamoxifen, 10 years of the drug reduces breast cancer death rates by a third in the first 10 years and by half after that. "Until now, there have been doubts wh...
Source: Guardian Unlimited Science - June 3, 2013 Category: Science Tags: The Guardian News Health Medical research Society Drugs UK news Breast cancer Science Source Type: news

First Comprehensive Analysis Reveals Long-term Effectiveness Of SERMs For Preventing Breast Cancer
Selective oestrogen receptor modulators (SERMs: tamoxifen, raloxifene, arzoxifene, and lasofoxifene) significantly reduce the risk of developing the most common type of breast cancer among women at both high and average risk of the disease* both during treatment, and for at least 5 years after stopping, according to the first comprehensive analysis of all SERM prevention trials to date published Online First in The Lancet... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 2, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Breast Cancer Drugs May Reduce Risks in Healthy High-Risk Women
Tamoxifen and raloxifene reduce the incidence of invasive breast cancer in women without cancer, but they also increase the risk of blood clots and other risks. (Source: Consultant Live)
Source: Consultant Live - April 22, 2013 Category: Primary Care Source Type: news

News From Annals Of Internal Medicine: 16 April 2013
1. Task Force Reviews Evidence for New Recommendations on Medications to Reduce Risk for Primary Breast Cancer High-risk women may derive the most benefit, least harms from preventive drug therapy Women at high risk for breast cancer may benefit most from preventive drug therapy. In 2002, the United States Preventive Services Task Force (USPSTF) recommended against routine use of tamoxifen and raloxifene for prevention of primary breast cancer for women at average risk... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 17, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Women at Risk for Breast Cancer Should Participate in Decisions About Risk-reducing Drugs
According to a draft recommendation recently introduced by the U.S. Preventive Services Task Force (USPSTF), physicians should strive to engage women at increased risk of breast cancer in the process of making decisions about medications that can reduce their risk. At-risk women who are deemed to be at low risk for adverse effects from these drugs could benefit from taking medications such as tamoxifen or raloxifene. (Source: AAFP Health of the Public)
Source: AAFP Health of the Public - April 16, 2013 Category: Primary Care Source Type: news

Chemoprevention for Women at High Risk for Breast CancerChemoprevention for Women at High Risk for Breast Cancer
The US Preventive Services Task Force has recommended the prophylactic use of tamoxifen and raloxifene in women at high risk for breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Discuss cancer-reducing drugs with women - panel
NEW YORK (Reuters Health) - Doctors should talk about breast cancer-reducing drugs with women and offer tamoxifen or raloxifene to those that have a high risk of cancer and aren't likely to suffer side effects, a government-backed panel said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Breast Cancer Drugs Urged for Healthy High-Risk Women
A panel of experts said tamoxifen and raloxifene may be worth taking to lower the risk of breast cancer despite the potential for serious side effects like blood clots and strokes.     (Source: NYT Health)
Source: NYT Health - April 15, 2013 Category: Consumer Health News Authors: By DENISE GRADY Tags: Tamoxifen (Drug) Breast Cancer raloxifene United States Preventive Services Task Force Source Type: news

Chemoprevention of Breast Cancer: Evidence of Broad BenefitChemoprevention of Breast Cancer: Evidence of Broad Benefit
A systematic review of tamoxifen and raloxifene in the prevention of breast cancer will inform an upcoming update from the USPSTF. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Drugs to Avert Breast Cancer Not Always Used (CME/CE)
(MedPage Today) -- Drugs including tamoxifen and raloxifene are effective in reducing breast cancer incidence in high-risk women, but their side effects have discouraged use, a systematic review found. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 15, 2013 Category: Consumer Health News Source Type: news

NICE issues draft guideline on familial breast cancer for consultation
Source: NICE Area: News The National Institute for Health and Clinical Excellence (NICE) has published a draft guideline on the management of familial breast cancer, for consultation.    The draft guideline makes provisional recommendations on issues including - when to offer genetic testing, what surveillance strategies should and should not be offered, and the use of tamoxifen or raloxifene  as treatments to prevent breast cancer.   The closing date for comments is 25 February 2013.   An embargoed version of the final guideline will be available to stakeholder organisations that comm...
Source: NeLM - News - January 16, 2013 Category: Drugs & Pharmacology Source Type: news

Breast cancer drugs set for preventative use
Almost all of the newspapers and their websites are leading with the news that the National Institute for Health and Clinical Excellence (NICE) has published draft guidelines recommending that women with a high risk of familial breast cancer should be offered preventative drug treatments. The news is based on draft guidelines released by NICE for the care of women at risk of developing breast cancer that runs in families (familial breast cancer). The new draft guidelines update the 2006 guidelines, and include new recommendations on genetic testing and monitoring of the disease.  New prop...
Source: NHS News Feed - January 15, 2013 Category: Consumer Health News Tags: Cancer QA articles Source Type: news

NICE considers treatment for breast cancer prevention
A proposed update to the National Institute for Health and Clinical Excellence's familial breast cancer clinical guideline is exploring whether hormone therapy could be given to at-risk women for up to five years to help cut their risk of getting the disease. According to the institute, for those for whom surgery is unsuitable, so-called 'chemoprevention' through drugs such as tamoxifen and raloxifene "may represent a more acceptable means of risk reduction", even though they are not licensed specifically for this use in the UK. (Source: NHS Networks)
Source: NHS Networks - January 15, 2013 Category: UK Health Authors: Maria Axford Source Type: news